CD19 CAR T Cells
Copyright policy )CD19 CAR T Cells
CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome. Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient to eliminate the targeted tumor. To view this Bench to Bedside, open or download the PDF.
- Memorial Sloan Kettering Cancer Center United States
Clinical Trials as Topic, T-Lymphocytes, Antigens, CD19, Receptors, Antigen, T-Cell, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Autografts, Lymphocyte Activation
Clinical Trials as Topic, T-Lymphocytes, Antigens, CD19, Receptors, Antigen, T-Cell, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Autografts, Lymphocyte Activation
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).105 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!